NKTR Nektar Therapeutics
Healthcare$65.71+0.00%OpenMarket Cap: $1.28B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.86
P/S
23.40
EV/EBITDA
-10.93
DCF Value
$-27.86
FCF Yield
-15.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-224.9%
Net Margin
-284.2%
ROE
-87.0%
ROA
-20.7%
ROIC
-17.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $10.9M | 98.6% | $-38.3M | $-44.9M | $— | — |
| Q4 null | $21.8M | 100.0% | $-19.1M | $-36.1M | $— | — |
| FY null | $55.2M | 100.0% | $-130.8M | $-164.1M | $— | — |
| Q3 null | $11.8M | 98.3% | $-31.5M | $-35.5M | $— | — |
| Q2 null | $11.2M | 100.0% | $-36.2M | $-41.6M | $— | — |
| Q1 null | $10.5M | 100.0% | $-44.5M | $-50.9M | $— | — |
| Q4 null | $29.2M | 72.7% | $14.3M | $7.3M | $— | — |
| FY null | $98.4M | 68.8% | $-105.2M | $-119.0M | $— | — |
| Q3 null | $24.1M | 81.6% | $-34.3M | $-37.1M | $— | — |
| Q2 null | $23.5M | 58.5% | $-49.8M | $-52.4M | $— | — |
| Q1 null | $21.6M | 60.6% | $-35.4M | $-36.8M | $— | — |
| Q4 2023 | $23.9M | 69.5% | $-33.5M | $-42.1M | $-3.30 | — |